Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Prior Authorization topic
No spam. Unsubscribe anytime.
Committee adopts amendment and advances bill limiting prior authorization for rare-disease treatments, 8-0
Summary
The committee adopted a technical amendment to clarify the definition of "off-label" and gave a do-pass recommendation, 8-0, to a governor-sponsored bill that shortens prior-authorization timelines for treatments for rare diseases and protects off-label use of FDA-approved medicines.
A governor-sponsored bill to limit prior authorization delays for rare-disease treatments received unanimous committee support after a clarifying amendment and testimony from patients and regulators.
The committee adopted an amendment that narrowed the definition of "off-label" use so it applies only to medications that are approved by the U.S. Food and Drug Administration but not approved for a specific condition or dosage. The sponsor said the change was intended to exclude unapproved products and to ensure the bill applies to prescription drugs that have FDA approval for some uses but not a labeled indication for a given rare disease.
Sponsor testimony and witnesses said the policy addresses long waits and multiple appeals that patients with rare conditions face when insurers require prior authorization for critical drugs. Former state representative Debbie Armstrong described her own experience with a rare autoimmune muscle disease and said multiple denials delayed treatment for weeks, leaving her functionally dependent until appeals succeeded. The Office of the Superintendent of Insurance and the Health Care Authority testified in support and said they helped craft the bill.
The bill sets time limits for medical-necessity determinations (seven days ordinarily and 24 hours under certain urgent conditions) and clarifies that off-label use, as amended, refers to FDA-approved medications without an approved indication for the specific condition. The committee recorded an 8-0 do-pass recommendation.
Committee action: Amendment adopted by voice; final committee recommendation to pass, 8-0. The bill was described as focused on rare diseases as defined by federal law (conditions affecting fewer than 200,000 people in the U.S.).
The bill now moves to subsequent committees where insurers, Medicaid and providers will work through implementation details such as appeals processes, timelines and interactions with existing step-therapy and prior-authorization statutes.
